

Certificate of Analysis

PASK, active

(Recombinant enzyme expressed in Sf21 insect cells) Item # 14-701, 14-701-K, 14-701M
Parent Lot # D12AP008N

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: *N*-terminal 6Histagged, recombinant, human PASK, amino acids 995—end, expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA agarose. Purity 60.9% by SDS-PAGE and Coomassie blue staining. MW = 41.5kDa.

Specific Activity (Parent lot# D12AP008N): 1211U/mg, where one unit of PASK, active activity is defined as 1nmol phosphate incorporated into 250μM (KKLNRTLSFAEPG) per minute at 30°C with a final ATP concentration of 100μM.

Formulation: 0.748mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.

Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.


Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


FOR IN VITRO RESEARCH USE ONLY NOT FOR USE IN HUMANS OR ANIMALS

Quality Control Testing

<u>Kinase Assay</u>: 0.9–18.7ng of this lot of enzyme phosphorylated 250μM (KKLNRTLSFAEPG) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.

MS Tryptic Fingerprint: Confirmed product identity as PASK with the translated native sequence listed on page three.





SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3µg of PASK, active.

Eurofins Pharma Discovery Services UK Limited Gemini Crescent Dundee Technology Park DUNDEE DD2 1SW United Kingdom T | +44 (0)1382 561600 F | +44 (0)1382 561601 www.eurofins.com/pharmadiscovery



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

- 5 x Reaction Buffer: 40mM MOPS-NaOH pH7.0, 1mM EDTA.
- KKLNRTLSFAEPG: Use at a final concentration of 250μM. Make up a 2.5mM stock. Use 2.5μl of stock per assay point.
- 3. PASK, active: Dilute with 20mM MOPS-NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 0.9–18.7ng per assay point.
- **4.** [γ -³³P]ATP: 2.5 x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

- 1. Add 5µl of 5 x reaction buffer per assay to wells.
- 2. Add 2.5µl of (KKLNRTLSFAEPG).
- 3. Add 2.5µl (0.9-18.7ng), PASK active.
- 4. Add 5µl of dH₂O.
- 5. Add 10 μ l of diluted [γ - 33 P]ATP mixture.
- 6. Incubate for 10 minutes at 30°C.
- 7. Stop the reaction by adding 5µl of 3% phosphoric acid.
- Transfer a 10µl aliquot onto the appropriate area of a P30 Filtermat.
- 9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
- 10. Wash the filtermat once for 2 minutes with methanol.
- 11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
- 12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

PASK Sequence Information

Protein Human PASK

<u>Tags</u> N-terminal 6His

Native sequence Y37 of recombinant sequence is equivalent to Y995 of human PASK

Accession number GenBank NM_015148

Recombinant PASK amino acid sequence:

```
1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF KGLRRQYSQK YSTMSPLGSG AFGFVWTAVD 61 KEKNKEVVVK FIKKEKVLED CWIEDPKLGK VTLEIAILSR VEHANIIKVL DIFENQGFFQ 121 LVMEKHGSGL DLFAFIDRHP RLDEPLASYI FRQLVSAVGY LRLKDIIHRD IKDENIVIAE 181 DFTIKLIDFG SAAYLERGKL FYTFCGTIEY CAPEVLMGNP YRGPELEMWS LGVTLYTLVF 241 EENPFCELEE TVEAAIHPPY LVSKELMSLV SGLLQPVPER RTTLEKLVTD PWVTQPVNLA 301 DYTWEEVFRV NKPESGVLSA ASLEMGNRSL SDVAQAQELC GGPVPGEAPN GQGCLHPGDP 361 RLLTS
```

Recombinant PASK nucleotide sequence:

```
1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
 61 tattttcagg gcgccatgga tccggaattc aaaggcctac gtcgacaata ctcccaaaag
121 tacagtacca tgagcccgct gggcagtggg gccttcggct tcgtgtggac tgctgtggac
181 aaggaaaaaa acaaggaggt ggtggtgaag tttattaaga aggagaaggt cttggaggat
241 tgttggattg aggatcccaa acttgggaaa gttactttag agatcgcaat tctatccagg
301 gtggagcacg ccaatatcat caaggtattg gatatatttg aaaaccaagg gttcttccag
361 cttgtgatgg agaagcacgg ctccggccta gacctcttcg ctttcatcga ccgccacccc
421 aggctggatg agcccctggc gagctacatc ttccgacaac tagtgtcagc agtgggatac
481 ctgcgcttga aggacatcat ccaccgtgac atcaaggatg agaacatcgt gatcgccgag
541 gacttcacaa tcaagctgat agactttggc tcggccgcct acttggaaaa gggaaaatta
601 ttttatactt tttgtgggac catcgagtac tgtgcaccgg aagttctcat ggggaatccc
661 tacagagggc cggagctgga gatgtggtct ctgggagtca ctctgtacac gctggtcttt
721 gaggagaacc ccttctgtga gctggaggag accgtggagg ctgccataca cccgccatac
781 ctggtgtcca aagaactcat gagccttgtg tctgggctgc tgcagccagt ccctgagaga
841 cgcaccacct tggagaagct ggtgacagac ccgtgggtaa cacagcctgt gaatcttgct
901 gactatacat gggaagaggt gtttcgagta aacaagccag aaagtggagt tctgtccgct
961 gcgagcctgg agatggggaa caggagcctg agtgatgtgg cccaggctca ggagctttgt
1021 gggggccccg ttccaggcga ggctcctaat ggccaaggct gtttgcatcc cggggatccc
1081 cgtctgctga ccagctaa
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services